TY - JOUR
T1 - Technetium-99m-labeled HL91 to identify tumor hypoxia: Correlation with fluorine-18-FDG
AU - Cook, G. J. R.
AU - Houston, S.
AU - Barrington, S. F.
AU - Fogelman, I.
N1 - M1 - 1
Times Cited: 57
PY - 1998/1
Y1 - 1998/1
N2 - Technetium-99m HL91 is a potential agent for imaging hypoxic tissue in vivo. A pilot evaluation using a prototype formulation assessed efficacy in tumor imaging and compared results with F-18-fluorodeoxyglucose (FDG) PET, Methods: Ten patients with malignant tumors were included, Tumors included carcinoma of the bronchus (n = 3), carcinoma of the thyroid (n = 2), lymphoma (n = 2), soft tissue sarcoma (n = 1), carcinoid (n = 1) and carcinoma of the breast (n = 1), Whole-body planar scans and localized SPECT scans were performed at 1 and 4 hr postinjection of 600 MBq Tc-99m HL91. Half-body and localized emission/transmission F-18-FDG PET scans were performed 60 min postinjection 370 MBq F-18-FDG in eight patients, Lesion-to-normal tissue background ratios were measured for all Tc-99m HL91 and F-18-FDG PET scans and percentage uptake and standardized uptake values measured for Tc-99m HL91 and F-18-FDG PET, respectively. Results: Technetium-99m HL91 showed visible uptake into the tumor area in all seven studies where the tumor was clearly identified by F-18-FDG PET; Tc-99m HL91 uptake was not detected in one study (carcinoid) in which F-18-FDG was weakly positive. Two further tumors, in which PET correlation was not available, showed accumulation of Tc-99m HL91. In two Tc-99m HL91 studies, abnormality was apparent only on SPECT images. Lesion-to-normal tissue background ratios for Tc-99m HL91 ranged from 1.22/2.53 at I hr and 1.33/2.89 at 4 hr on planar images and 1.23/5.2 and 1.67/14.6 on SPECT images, respectively. Conclusion: In this study, the use of Tc-99m HL91 resulted in uptake in the majority of malignant tumors identified by F-18-FDG-PET. Technetium-99m HL91 exhibits good imaging characteristics, with imaging at 4 hr providing good lesion-to-normal tissue background ratios, that are further enhanced by SPECT.
AB - Technetium-99m HL91 is a potential agent for imaging hypoxic tissue in vivo. A pilot evaluation using a prototype formulation assessed efficacy in tumor imaging and compared results with F-18-fluorodeoxyglucose (FDG) PET, Methods: Ten patients with malignant tumors were included, Tumors included carcinoma of the bronchus (n = 3), carcinoma of the thyroid (n = 2), lymphoma (n = 2), soft tissue sarcoma (n = 1), carcinoid (n = 1) and carcinoma of the breast (n = 1), Whole-body planar scans and localized SPECT scans were performed at 1 and 4 hr postinjection of 600 MBq Tc-99m HL91. Half-body and localized emission/transmission F-18-FDG PET scans were performed 60 min postinjection 370 MBq F-18-FDG in eight patients, Lesion-to-normal tissue background ratios were measured for all Tc-99m HL91 and F-18-FDG PET scans and percentage uptake and standardized uptake values measured for Tc-99m HL91 and F-18-FDG PET, respectively. Results: Technetium-99m HL91 showed visible uptake into the tumor area in all seven studies where the tumor was clearly identified by F-18-FDG PET; Tc-99m HL91 uptake was not detected in one study (carcinoid) in which F-18-FDG was weakly positive. Two further tumors, in which PET correlation was not available, showed accumulation of Tc-99m HL91. In two Tc-99m HL91 studies, abnormality was apparent only on SPECT images. Lesion-to-normal tissue background ratios for Tc-99m HL91 ranged from 1.22/2.53 at I hr and 1.33/2.89 at 4 hr on planar images and 1.23/5.2 and 1.67/14.6 on SPECT images, respectively. Conclusion: In this study, the use of Tc-99m HL91 resulted in uptake in the majority of malignant tumors identified by F-18-FDG-PET. Technetium-99m HL91 exhibits good imaging characteristics, with imaging at 4 hr providing good lesion-to-normal tissue background ratios, that are further enhanced by SPECT.
M3 - Article
SN - 0161-5505
VL - 39
SP - 99
EP - 103
JO - Journal of Nuclear Medicine
JF - Journal of Nuclear Medicine
IS - 1
ER -